We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status More information
         
ACT-541468 Dual orexin receptor antagonist Insomnia Phase 3 Investor webcast
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Investor webcast
Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Phase 3 Investor webcast
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3 Investor webcast
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2  
Selatogrel P2Y12 receptor antagonist Acute coronary syndrome (ACS) Phase 2  
ACT-774312 CRTH2 receptor antagonist Nasal polyposis Phase 2  
ACT-519276 GBA2/GCS inhibitor Orphan CNS diseases Phase 1  
ACT-539313 Selective orexin 1 receptor antagonist Anxiety Phase 1  
ACT-709478 T-type calcium channel blocker Epilepsy Phase 1  
ACT-1004-1239 - Cancer Immunotherapy / Immunology Phase 1  


* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide
** Market registration trials are also being conducted in Japan

"I enjoy working in a multicultural environment because it enriches the workplace and my knowledge of the world."

Associate Clinical Research Physician, Clinical Science